LUMINEX MULTIPLEX ASSAY SERVICE

Human Cytokine Storm Luminex Panel (21-Plex)

Simultaneous quantification of 21 key cytokines and chemokines involved in hyperinflammatory syndromes — cytokine release syndrome (CRS), sepsis, hemophagocytic lymphohistiocytosis (HLH), and COVID-19-associated cytokine storm — in a single well using Luminex xMAP technology. A pre-configured, validated panel from 25 μL of serum or plasma.

21 TargetsHuman25 μL SampleSub-pg/mL
Request a Quote View Analytes
21-Plex Cytokine Storm
Brown University
Harvard University
Imperial College London
University of Florida
Tulane University
Abata Therapeutics
AlzeCure Pharma

Cytokine storm is a life-threatening hyperinflammatory state driven by an uncontrolled positive feedback loop between immune cells and cytokines. Unlike chronic low-grade inflammation (e.g., rheumatoid arthritis), cytokine storm is acute, explosive, and systemic — characterized by massively elevated IL-6, TNF-α, IL-1β, IFN-γ, and chemokines within hours to days of the triggering event. The clinical syndromes encompassed by cytokine storm include cytokine release syndrome (CRS) following CAR-T therapy, sepsis-associated hyperinflammation, hemophagocytic lymphohistiocytosis (HLH/MAS), and severe COVID-19. The shared pathophysiology across these conditions — myeloid cell activation, endothelial damage, and multi-organ failure driven by the same core cytokine network — makes a standardized multiplex panel for cytokine storm assessment essential.

Creative Proteomics offers the Human Cytokine Storm 21-Plex Panel based on the Luminex xMAP platform for simultaneous quantification of 21 cytokines and chemokines centrally implicated in hyperinflammatory syndromes. The panel covers the core CRS cytokines (IL-6, TNF-α, IL-1β, IFN-γ, GM-CSF), counter-regulatory mediators (IL-10, IL-1RA), Th1/Th2/Th17 effector cytokines (IL-2, IL-4, IL-5, IL-12p70, IL-13, IL-17A, IL-18), type I interferon (IFN-α), myeloid growth factors (G-CSF, GM-CSF), and key chemokines (IL-8, IP-10, MCP-1, MIP-1α, MIP-1β). Validated for serum and plasma, the panel is compatible with MAGPIX, Luminex 200, and FLEXMAP 3D systems.

Unlike a broad inflammation panel where you configure analytes, the Cytokine Storm 21-Plex is a fixed, pre-validated panel — its composition has been optimized for the hyperinflammatory response and is directly aligned with published biomarker signatures in CRS, sepsis, and HLH. A single 25 μL sample generates a complete cytokine storm profile in ~4 hours.

Panel Specifications
TechnologyLuminex xMAP
Panel Size21-Plex (fixed, pre-validated)
SpeciesHuman
Sample TypesSerum, EDTA/Heparin Plasma
Sample Volume25 μL per well
SensitivitySub-pg/mL
Assay Time~4 hours

Complete Analyte List — Cytokine Storm 21-Plex Panel

The 21-Plex is a fixed, pre-validated panel optimized for hyperinflammatory syndromes. Analytes are organized by their role in the cytokine storm cascade.

Panel Plex Key Targets
Human Cytokine Storm Panel 21 G-CSF, GM-CSF, IFN-α, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-13, IL-17A, IL-18, TNF-α, TNF-β (Lymphotoxin), IP-10 (CXCL10), MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4) Inquiry

Analyte Functional Grouping

Category Analytes Role in Cytokine Storm
Core CRS Mediators IL-6, TNF-α, IL-1β, IFN-γ, GM-CSF IL-6 is the central amplifier — the strongest predictor of CRS severity and the primary target of tocilizumab intervention. TNF-α and IL-1β drive endothelial activation and vascular leak. IFN-γ reflects T and NK cell activation. GM-CSF links T cell activation to myeloid expansion
Counter-Regulatory IL-10 The IL-6/IL-10 ratio is a validated predictor of CRS severity and mortality — elevated IL-6 without adequate IL-10 counter-regulation predicts progression to severe CRS. IL-10 alone may paradoxically be elevated in severe disease as a compensatory response
Th1/Th2/Th17 Effectors IL-2, IL-4, IL-5, IL-12p70, IL-13, IL-17A, IL-18 Complete T helper subset coverage. IL-18 (inflammasome-dependent) synergizes with IL-12 to drive IFN-γ production. IL-17A contributes to neutrophil recruitment and tissue inflammation
Type I Interferon IFN-α Elevated in viral-driven cytokine storm (COVID-19, influenza) and SLE-associated MAS. Suppressed in bacterial sepsis. IFN-α levels help distinguish viral from bacterial hyperinflammation
Myeloid Growth Factors G-CSF, GM-CSF Drive emergency granulopoiesis during hyperinflammation. G-CSF contributes to the neutrophilia characteristic of severe CRS and sepsis. GM-CSF is a critical upstream amplifier of myeloid activation
Chemokine Recruitment IL-8, IP-10, MCP-1, MIP-1α, MIP-1β IL-8 drives neutrophil chemotaxis. MCP-1 recruits monocytes. IP-10 directs T cell trafficking and is elevated in ICANS (neurotoxicity). MIP-1α and MIP-1β amplify myeloid recruitment
How is this panel different from the Inflammation 20-48 Plex? The Inflammation Panel is configurable (20 to 48-plex from 90+ analytes) designed for general inflammation research. The Cytokine Storm 21-Plex is a fixed, pre-validated panel specifically composed for hyperinflammatory syndromes. It includes TNF-β, IL-18, and IFN-α — markers particularly relevant to cytokine storm that are not in the core Inflammation 20-Plex. If your research spans multiple inflammatory conditions, the configurable Inflammation Panel provides flexibility. If your focus is specifically CRS, sepsis, or HLH, the 21-Plex provides a validated, ready-to-use solution.

Cytokine Storm Is Not One Disease: Distinct Cytokine Signatures

Different hyperinflammatory syndromes produce different — and characteristically distinct — cytokine profiles. The 21-Plex captures the full spectrum, enabling syndrome-specific pattern recognition.

CRS (CAR-T Therapy)

Dominant: IL-6, IFN-γ, GM-CSF, IL-10. CRS is driven by CAR-T cell activation triggering macrophage production of IL-6. IFN-γ reflects CAR-T expansion. The IL-6 peak typically occurs 2-5 days post-infusion. IL-10 rises in parallel as a compensatory response. IL-1β and TNF-α are also elevated but less consistently than IL-6. A rapid rise in IL-6 >1000 pg/mL within 72 hours of infusion is associated with progression to grade ≥3 CRS.

Key monitoring window: Day 0 to Day 7 post-infusion

Sepsis / Septic Shock

Dominant: IL-6, IL-8, MCP-1, IL-10. Bacterial sepsis triggers massive myeloid activation and complement cascade. IL-6 and IL-8 are the most consistently elevated cytokines. The IL-6/IL-10 ratio predicts mortality: a high ratio indicates uncontrolled inflammation; a low ratio may indicate immunoparalysis. Unlike CRS, IFN-γ is often not the dominant driver, and TNF-α may be only modestly elevated.

Key monitoring window: First 24-72 hours after presentation

HLH / MAS

Dominant: IFN-γ, IL-18, IL-6, TNF-α. HLH is characterized by defective NK and CD8+ T cell cytotoxicity leading to persistent antigen-driven immune activation. IFN-γ is massively elevated (often >1000 pg/mL) and is the primary disease driver. IL-18 is a distinguishing feature — elevated IL-18 with modest IL-6 suggests MAS rather than sepsis. CXCL9 (MIG) and IP-10 are IFN-γ-inducible and further elevated.

Key distinguishing marker: IL-18 >1000 pg/mL suggests HLH/MAS over sepsis

COVID-19 Hyperinflammation

Dominant: IL-6, IP-10, MCP-1, TNF-α. COVID-19 cytokine storm is distinct from both CRS and classical sepsis. IL-6 levels are elevated but typically lower than in CRS (median 50-200 pg/mL vs >1000 pg/mL). IP-10 and MCP-1 are disproportionately elevated, reflecting the pulmonary-centric inflammation. IFN-α is elevated early (antiviral response) but may decline in severe disease. The IL-6/IL-10 ratio at admission predicts ICU requirement.

Key distinguishing marker: High IP-10 + MCP-1 with moderate IL-6 suggests COVID-19 over sepsis

Why syndrome-specific cytokine profiling matters: A patient with IL-6 = 500 pg/mL could have CRS, sepsis, or COVID-19. The distinction — and therefore the therapeutic decision (tocilizumab for CRS, antibiotics for sepsis, dexamethasone for COVID-19) — depends on the broader cytokine pattern. IFN-γ > IL-6 suggests CRS. IL-18 >1000 pg/mL suggests HLH. High IP-10 with moderate IL-6 suggests COVID-19. A panel measuring only IL-6 cannot make these distinctions; the 21-Plex provides the full cytokine context.

Luminex Multiplex vs ELISA for Cytokine Storm Assessment

Cytokine storm is defined by the simultaneous elevation of multiple cytokines. The pattern — not any single measurement — characterizes the specific hyperinflammatory syndrome and guides therapeutic research.

Parameter Luminex 21-Plex Traditional ELISA (21 assays)
Targets per Well 21 1
Sample Volume 25 μL 525–1,050 μL total
Time to Full Profile ~4 hours 63–84 hours
Syndrome Discrimination IL-6/IL-10 ratio, IFN-γ/IL-6 ratio, IL-18 dominance — all from same aliquot Each ratio requires 2-3 separate assays — between-assay CV invalidates cross-analyte comparisons

In cytokine storm, the IL-6/IL-10 ratio and the IFN-γ/IL-6 ratio have direct clinical implications. A patient with IL-6 elevated and IL-10 low is in an uncontrolled hyperinflammatory state. A patient with IL-6 elevated and IL-10 proportionally elevated is mounting an appropriate counter-regulatory response. A patient with IFN-γ dominating over IL-6 likely has CRS or HLH rather than sepsis. These distinctions can only be made when all relevant cytokines are measured simultaneously from the same sample aliquot — which is precisely what the 21-Plex delivers.

Sample Requirements for Cytokine Storm Luminex Assays

Cytokine storm samples require particular care because cytokine levels can change rapidly over hours. Standardize collection timing and processing protocols for all samples within a study.

Sample Type Volume Requirement
Serum 25 μL Collect in SST or red-top tubes; allow 30 min clotting at room temperature; centrifuge at 1,500g for 10 min. For CRS monitoring, standardize time post-CAR-T infusion (e.g., Day 0, +1, +3, +5, +7, +14)
EDTA/Heparin Plasma 25 μL Centrifuge within 30 min at 2,500g for 15 min. EDTA plasma preferred. Heparin may interfere with some detection antibodies
Minimum Project Size — One 96-well plate; for CRS studies, 39 samples in duplicate per plate accommodates ~5 participants × 3 time points
Sample Storage — -80°C; IL-6 and TNF-α are relatively stable; IL-17A and IFN-γ more labile. Avoid repeated freeze-thaw
Shipping — Dry ice; samples must remain frozen throughout transit
CRS-Specific Note — IL-6 levels can increase >100-fold within 24 hours during CRS onset. If serial samples are being analyzed, ensure all samples from a participant are run on the same plate to eliminate inter-plate variability in the longitudinal trajectory

Deliverables & Quality Metrics

Every cytokine storm Luminex assay includes a comprehensive data package with full quality control documentation.

Data Package
  • Raw fluorescence intensities (.csv)
  • Calculated concentrations (pg/mL) for all 21 analytes
  • Key ratios: IL-6/IL-10, IFN-γ/IL-6 (optional)
  • 5PL standard curves for each analyte (R² >0.99)
  • Full QC report (.xlsx format)
Quality Control
  • Standard curve: 7-point dilution series, 5PL fit
  • Intra-assay CV <15%
  • Inter-assay CV <15%
  • Spike recovery: 80–120% in serum/plasma matrix
Assay Performance
  • Duplicate measurements for all samples
  • All time points from the same participant on the same plate
  • Method summary with reagent lot numbers
  • LLOD and LLOQ per analyte reported
  • Platform: Luminex xMAP, MAGPIX, Luminex 200, FLEXMAP 3D

Related Panels

Cytokine storm is the most extreme manifestation of inflammation. These panels support the full spectrum from chronic inflammation to acute hyperinflammation.

Human Inflammation Panel (20-48 Plex)
  • Targets: 90+ configurable inflammatory markers
  • Platform: Luminex
  • Plex: 20 to 48-Plex
View Details
Human Cell Therapy Cytokine Panel
  • Targets: IL-6, IFN-γ, GM-CSF, IL-10, IL-2, IP-10
  • Platform: Luminex
  • Plex: 20/25-Plex
View Details
Human Immune Checkpoint 37-Plex
  • Targets: PD-1, PD-L1, CTLA-4, TIM-3, LAG-3
  • Platform: Luminex
  • Plex: 37-Plex
View Details
Human Complement Factor Panel
  • Targets: C1q, C3, C4, Factor B, Properdin
  • Platform: Luminex
  • Plex: 7-8-Plex
View Details
Human Coagulation Factor Panel
  • Targets: vWF, Antithrombin, Factor VIII, Prothrombin
  • Platform: Luminex
  • Plex: 4/6-Plex
View Details
Human Cardiac Remodeling 8-Plex
  • Targets: Galectin-3, ST2, OPN, IL-33, PTX3, TREM-1
  • Platform: Luminex
  • Plex: 8-Plex
View Details
Human GvHD Biomarker 8-Plex
  • Targets: ST2, REG3α, TNFR1, IL-6, Elafin, HGF
  • Platform: Luminex
  • Plex: 8-Plex
View Details
Serum & Plasma Cytokine Assay
  • Targets: Collection & handling protocols
  • Platform: Luminex
  • Focus: Sample preparation guide
View Details
← All Human PanelsBrowse species overview

Frequently Asked Questions About Cytokine Storm Panel

Common questions about our human cytokine storm Luminex multiplex panel service.

How is this different from the Human Inflammation Panel?
The Inflammation Panel (20-48 plex) is a configurable panel for general inflammation research across many disease contexts. The Cytokine Storm 21-Plex is a fixed, pre-validated panel specifically composed for acute hyperinflammatory syndromes (CRS, sepsis, HLH). It includes TNF-β, IL-18, and IFN-α — markers particularly relevant to cytokine storm that differ from the core Inflammation 20-Plex. Choose the Inflammation Panel for configurable flexibility across multiple research areas. Choose the Cytokine Storm Panel when your research is specifically focused on acute hyperinflammation.
Why does this panel include TNF-β and IL-18?
TNF-β (Lymphotoxin-α) is produced by activated T cells and contributes to the lymphoid organ damage seen in severe CRS and HLH. IL-18 is an inflammasome-dependent cytokine that synergizes with IL-12 to drive massive IFN-γ production. IL-18 is a distinguishing biomarker: elevated IL-18 (>1,000 pg/mL) with modest IL-6 suggests HLH/MAS rather than sepsis, while the reverse pattern favors sepsis. These two analytes are not typically included in standard inflammation panels but are specifically relevant to hyperinflammatory syndromes.
What is the IL-6/IL-10 ratio and why does it matter in cytokine storm?
The IL-6/IL-10 ratio reflects the balance between hyperinflammation and counter-regulation. Both IL-6 and IL-10 are typically elevated in cytokine storm, but their ratio carries prognostic information. A very high IL-6/IL-10 ratio (>20) indicates inflammation outpacing regulatory control, associated with progression to severe CRS and organ failure. A declining IL-6/IL-10 ratio during anti-inflammatory intervention (e.g., tocilizumab, corticosteroids) suggests effective restoration of inflammatory homeostasis. This ratio can only be reliably calculated when both cytokines are measured simultaneously from the same sample — a fundamental advantage of multiplex over individual ELISA.
Can this panel distinguish between different causes of cytokine storm?
The 21-Plex captures the full cytokine profile, enabling syndrome-specific pattern recognition. A very high IFN-γ/IL-6 ratio with elevated IL-18 suggests CRS or HLH. High IL-8 and MCP-1 with moderate IL-6 suggests sepsis. High IP-10 and MCP-1 with moderate IL-6 and elevated IFN-α suggests COVID-19. These distinctions require the complete 21-analyte profile — measuring only IL-6 and a few other markers cannot differentiate between syndromes that require different therapeutic approaches.
What sample collection schedule is recommended for CRS monitoring?
Standard schedule: pre-infusion (baseline), Day 0 (+4h, +8h post-infusion), Day 1, Day 3, Day 5, Day 7, Day 10, Day 14. The peak cytokine window is typically Day 2-5 for IL-6 and Day 5-7 for IFN-γ. If resources are limited, prioritize Days 0, 3, 5, 7, and 14. For ICANS (neurotoxicity) monitoring, extend collection to Day 28 and include CSF when clinically indicated. All time points from the same participant should be run on the same Luminex plate to ensure longitudinal data integrity.
Is this panel suitable for non-human samples in preclinical CRS models?
This panel is validated and optimized for human cytokines. For preclinical CRS models, we offer species-specific panels: our Mouse Metabolism 8-Plex, Mouse Inflammatory Panel, and NHP Cytokine Panels are appropriate for murine and primate cytokine storm models respectively. Human-specific panels should not be used for animal samples due to antibody species specificity. Contact us for guidance on the appropriate preclinical panel for your model.

Interested in Cytokine Storm Profiling?

Contact us to discuss your cytokine storm study requirements, sample collection schedule for CRS monitoring, and panel configuration. We respond within 24 hours.

Request a Quote
For Research Use Only. Not for use in diagnostic or clinical procedures.

Online Inquiry

×
0
Inquiry Basket
Inquiry

Submit the form below to download the PDF!

* I agree to receive other communications from Creative Proteomics, which may contain technical or marketing information. You can unsubscribe from these communications at any time.